================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
FORM 10-Q/A
AMENDMENT NO. 1 TO FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2002
COMMISSION FILE NUMBER: 0-26068
ACACIA RESEARCH CORPORATION
---------------------------
(Exact Name of Registrant as Specified in its Charter)
DELAWARE 95-4405754
-------- ----------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
Incorporation or organization)
500 NEWPORT CENTER DRIVE, NEWPORT BEACH, CA 92660
-----------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (949) 480-8300
--------------
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [ X ] No [ ]
At May 10, 2002, the registrant had 19,629,376 shares of common stock,
$0.001 par value, issued and outstanding.
================================================================================
EXPLANATORY NOTE
This quarterly report on Form 10-Q/A for the quarterly period ended June 30,
2002 is being filed solely to amend the list of exhibits included in Item 6
therein and to file a new Exhibit 10.1. Exhibit 10.1 is hereby filed pursuant to
a confidential treatment request filed with the Securities and Exchange
Commission. The Form 10-Q/A constitutes Amendment No. 1 to Acacia Research
Corporation's Quarterly Report on Form 10-Q for the quarterly period ended June
30, 2002.
PART II
OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
10.1* First Amendment, dated November 30, 2001, to the License and Supply
Agreement, dated as of July 1, 2001, between CombiMatrix Corporation
and Roche Diagnostics GmbH
* Portions of this Exhibit have been omitted pursuant to a request for
confidential treatment and have been filed separately with the United States
Securities and Exchange Commission.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ACACIA RESEARCH CORPORATION
DATED: September 26, 2002 /s/ Paul Ryan
-----------------------------------
Paul Ryan
Chief Executive Officer
(Authorized Signatory)
DATED: September 26, 2002 /s/ Clayton J. Haynes
-----------------------------------
Clayton J. Haynes
Chief Financial Officer/Treasurer
(Principal Financial Officer)
EXHIBIT INDEX
Exhibit Number Exhibit
- -------------- -------
10.1* First Amendment, dated November 30, 2001, to the License
and Supply Agreement, dated as of July 1, 2001, between
CombiMatrix Corporation and Roche Diagnostics GmbH
* Portions of this Exhibit have been omitted pursuant to a request for
confidential treatment and have been filed separately with the United States
Securities and Exchange Commission.